FR13C0071I2 - Compose diarylhydantoine - Google Patents

Compose diarylhydantoine

Info

Publication number
FR13C0071I2
FR13C0071I2 FR13C0071C FR13C0071C FR13C0071I2 FR 13C0071 I2 FR13C0071 I2 FR 13C0071I2 FR 13C0071 C FR13C0071 C FR 13C0071C FR 13C0071 C FR13C0071 C FR 13C0071C FR 13C0071 I2 FR13C0071 I2 FR 13C0071I2
Authority
FR
France
Prior art keywords
diarylhydantoine
compound
diarylhydantoine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0071C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0071(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of FR13C0071I1 publication Critical patent/FR13C0071I1/fr
Application granted granted Critical
Publication of FR13C0071I2 publication Critical patent/FR13C0071I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)
FR13C0071C 2005-05-13 2013-12-18 Compose diarylhydantoine Active FR13C0071I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06
PCT/US2006/011417 WO2006124118A1 (fr) 2005-05-13 2006-03-29 Composes diarylhydantoines

Publications (2)

Publication Number Publication Date
FR13C0071I1 FR13C0071I1 (fr) 2014-01-31
FR13C0071I2 true FR13C0071I2 (fr) 2015-11-20

Family

ID=37431537

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0071C Active FR13C0071I2 (fr) 2005-05-13 2013-12-18 Compose diarylhydantoine

Country Status (30)

Country Link
EP (5) EP3970721A1 (fr)
JP (13) JP4644737B2 (fr)
KR (12) KR101782236B1 (fr)
CN (6) CN105037273B (fr)
AT (1) ATE541571T1 (fr)
AU (1) AU2006248109B2 (fr)
BE (1) BE2013C074I2 (fr)
BR (1) BRPI0610359B8 (fr)
CA (1) CA2608436C (fr)
CY (2) CY1112798T1 (fr)
DK (2) DK1893196T4 (fr)
ES (2) ES2378778T5 (fr)
FR (1) FR13C0071I2 (fr)
HK (1) HK1217103A1 (fr)
HR (2) HRP20120323T4 (fr)
HU (1) HUS1300076I1 (fr)
IL (4) IL187328A (fr)
LU (1) LU92338I2 (fr)
ME (1) ME01992B (fr)
MX (4) MX346924B (fr)
NO (4) NO339997B1 (fr)
NZ (3) NZ564223A (fr)
PL (2) PL2444085T3 (fr)
PT (2) PT1893196E (fr)
RS (2) RS53967B1 (fr)
RU (3) RU2448096C3 (fr)
SG (1) SG10201703816SA (fr)
SI (2) SI1893196T2 (fr)
WO (1) WO2006124118A1 (fr)
ZA (2) ZA200710870B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709193B1 (fr) 2003-12-19 2011-03-16 The Regents of The University of California Procedes et materiaux pour evaluer des therapies du cancer de la prostate
WO2005099693A2 (fr) 2004-02-24 2005-10-27 The Regents Of The University Of California Methodes et substances permettant d'evaluer des therapies du cancer de la prostate, et composes s'y rapportant
CA2608436C (fr) * 2005-05-13 2015-03-24 The Regents Of The University Of California Composes diarylhydantoines et leur utilisation dans le traitement de troubles hyperproliferants
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) * 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
WO2008093838A1 (fr) * 2007-02-01 2008-08-07 Chugai Seiyaku Kabushiki Kaisha Dérivé de pyridyl imidazolidine ayant un groupe sulfamoyle, et utilisation pharmaceutique de ce dérivé
WO2008119015A2 (fr) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthèse de dérivés de la thiohydantoïne
EP2220050A2 (fr) * 2007-10-26 2010-08-25 The Regents Of The University Of California Composés de diarylhydantoïne
US8524755B2 (en) * 2009-02-24 2013-09-03 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
KR20120036842A (ko) * 2009-05-12 2012-04-18 코닌클리케 필립스 일렉트로닉스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR101456994B1 (ko) * 2009-09-10 2014-11-04 통유지 안드로겐 수용체 길항제 및 그의 용도
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JP2013504531A (ja) 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
PL2509961T3 (pl) 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
SG10201907588XA (en) * 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
HUE038637T2 (hu) * 2010-02-24 2018-12-28 Medivation Prostate Therapeutics Llc Eljárás a diaril-tiohidantoin és a diaril-hidantoin vegyületek szintetizálására
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
ES2560304T3 (es) 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
CN103608333B (zh) * 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
KR101958177B1 (ko) 2011-04-21 2019-03-15 오리온 코포레이션 안드로겐 수용체 조절성 카복스아미드
EP2718285B1 (fr) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
CN103159680A (zh) 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013175215A1 (fr) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles en tant qu'inhibiteurs de kv3
EP2852588B8 (fr) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Dérivés d'hydantoïne en tant qu'inhibiteurs de kv3
KR102189940B1 (ko) * 2012-09-04 2020-12-14 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 이미다졸린 유도체, 이의 제조 방법, 및 이들의 의약에서의 용도
TWI673051B (zh) * 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
EP2895464A4 (fr) * 2012-09-11 2016-06-15 Reddys Lab Ltd Dr Formes polymorphes d'enzalutamide et leur préparation
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
US9944607B2 (en) 2012-10-16 2018-04-17 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
CA2889756C (fr) * 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Composes de thiohydantoine en tant que modulateurs du recepteur androgenique
DK2945628T3 (da) 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (fr) * 2013-04-10 2014-10-16 Shilpa Medicare Limited 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe
EP3010889B1 (fr) 2013-06-20 2018-10-03 Bayer CropScience Aktiengesellschaft Dérivés d'arylsulfure et d'arylsulfoxyde comme acaricides et insecticides
WO2015018356A1 (fr) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 Dérivé de diarylhydantoïne et procédé de préparation, composition pharmaceutique et utilisation correspondants
WO2015042170A1 (fr) 2013-09-17 2015-03-26 Wayne State University Compositions et utilisations de combinaisons d'indoles associés à dim et de composés anti-androgène sélectionnés
RU2016110546A (ru) * 2013-09-19 2017-10-24 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированная лекарственная терапия
CN105188699B (zh) * 2013-10-14 2017-04-26 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
EP3063135A1 (fr) 2013-10-31 2016-09-07 Sun Pharmaceutical Industries Ltd Procédé de préparation d'enzalutamide
WO2015092617A1 (fr) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Procédé et intermédiaires pour la préparation d'enzalutamide
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
WO2015121768A1 (fr) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Procédé de préparation d'enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (fr) 2014-06-20 2015-12-23 England Pamela M Antagonistes du récepteur des androgènes
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
EA201791222A1 (ru) 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
HK1245791A1 (zh) * 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
US10118899B2 (en) 2015-05-29 2018-11-06 Astellas Pharma, Inc. Production method of enzalutamide crystal form
SMT202000258T1 (it) * 2015-09-10 2020-07-08 Jiangsu Hengrui Medicine Co Forma cristallina di inibitore del recettore degli androgeni e procedimento di preparazione dello stesso
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN110167556A (zh) * 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
US10933059B2 (en) 2016-12-16 2021-03-02 Kangpu Biopharmaceuticals. Ltd. Combination, application thereof and treatment method
JP7172997B2 (ja) 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
US20220242829A1 (en) 2019-06-27 2022-08-04 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
US20220347102A1 (en) 2019-10-03 2022-11-03 Synthon B.V. Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (fr) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Formulation d'enzalutamide
BR112023002295A2 (pt) 2020-08-13 2023-03-14 Pfizer Terapia de combinação
TW202237615A (zh) 2020-12-11 2022-10-01 南韓商日東製藥股份有限公司 作為雄激素受體及磷酸二酯酶雙重抑制劑的新穎化合物
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
EP4112603A1 (fr) 2021-06-29 2023-01-04 Química Sintética, S.A. Procédés de la préparation d'antiandrogènes non stéroïdiens
KR102861133B1 (ko) 2021-10-13 2025-09-16 주식회사 엘지에너지솔루션 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520B (zh) * 2022-01-28 2025-04-25 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
CN117327019A (zh) * 2022-06-23 2024-01-02 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂的应用
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
EP4374853A1 (fr) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Formulation solide d'enzalutamide
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
WO2025125565A1 (fr) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Comprimé comprenant de l'enzalutamide
WO2025210510A1 (fr) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg et rb1 comme biomarqueurs prédictifs de traitement par inhibiteur de parp
WO2026078615A1 (fr) 2024-10-09 2026-04-16 Pfizer Inc. Association de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate métastatique résistant à la castration
WO2026078619A1 (fr) 2024-10-09 2026-04-16 Pfizer Inc. Association de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate métastatique résistant à la castration

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
SU1380610A3 (ru) * 1982-12-06 1988-03-07 Пфайзер Инк. (Фирма) Способ получени спирогетероазолидиндионов или их фармацевтически приемлемых солей
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
WO1995019770A1 (fr) † 1994-01-21 1995-07-27 Sepracor, Inc. Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
PL346795A1 (en) 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
AU2003279442A1 (en) 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
WO2005099693A2 (fr) * 2004-02-24 2005-10-27 The Regents Of The University Of California Methodes et substances permettant d'evaluer des therapies du cancer de la prostate, et composes s'y rapportant
KR20070106969A (ko) * 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
CA2608436C (fr) * 2005-05-13 2015-03-24 The Regents Of The University Of California Composes diarylhydantoines et leur utilisation dans le traitement de troubles hyperproliferants
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
EP3106162A1 (fr) 2016-12-21
ES2535179T3 (es) 2015-05-06
EP1893196B1 (fr) 2012-01-18
KR20170107585A (ko) 2017-09-25
ZA200710870B (en) 2012-06-27
JP2025166151A (ja) 2025-11-05
JP2022101657A (ja) 2022-07-06
HRP20150437T1 (xx) 2015-06-05
RS53967B1 (sr) 2015-08-31
ES2378778T3 (es) 2012-04-17
DK1893196T4 (en) 2015-10-19
PL1893196T5 (pl) 2015-12-31
KR20210136161A (ko) 2021-11-16
HUS1300076I1 (hu) 2013-12-17
HK1217103A1 (zh) 2016-12-23
KR20140141676A (ko) 2014-12-10
KR20150086567A (ko) 2015-07-28
BRPI0610359A2 (pt) 2010-06-15
KR102020721B1 (ko) 2019-09-10
JP2011068653A (ja) 2011-04-07
CN110003114B (zh) 2023-01-17
MX346924B (es) 2017-04-05
JP4644737B2 (ja) 2011-03-02
CN101222922A (zh) 2008-07-16
NZ710355A (en) 2017-01-27
KR20130060369A (ko) 2013-06-07
KR101431407B1 (ko) 2014-08-18
DK1893196T3 (da) 2012-04-10
CY2013047I2 (el) 2015-11-04
CN120682155A (zh) 2025-09-23
MX2007014132A (es) 2008-04-09
JP2015098497A (ja) 2015-05-28
FR13C0071I1 (fr) 2014-01-31
NO2017019I2 (no) 2017-05-04
CN102584712A (zh) 2012-07-18
JP2012236843A (ja) 2012-12-06
JP5138753B2 (ja) 2013-02-06
CN110003114A (zh) 2019-07-12
SI1893196T2 (sl) 2015-10-30
RS52274B (sr) 2012-10-31
AU2006248109A1 (en) 2006-11-23
ZA201201793B (en) 2015-12-23
EP1893196B2 (fr) 2015-07-29
EP3970721A1 (fr) 2022-03-23
NZ591119A (en) 2012-08-31
MX2019015200A (es) 2020-02-05
KR101515335B1 (ko) 2015-04-24
JP2016183200A (ja) 2016-10-20
RS52274B2 (sr) 2018-05-31
BE2013C074I2 (fr) 2025-09-17
PL1893196T3 (pl) 2012-06-29
EP2444085A1 (fr) 2012-04-25
ES2378778T5 (es) 2015-09-25
ATE541571T1 (de) 2012-02-15
KR101332924B1 (ko) 2013-11-26
KR20110041580A (ko) 2011-04-21
MX2022009759A (es) 2022-09-05
NO20161996A1 (no) 2008-02-08
MX394667B (es) 2025-03-21
SI1893196T1 (sl) 2012-06-29
CY1112798T1 (el) 2015-11-04
JP2024153705A (ja) 2024-10-29
EP1893196A1 (fr) 2008-03-05
DK2444085T3 (en) 2015-04-27
PT1893196E (pt) 2012-04-03
NO20180225A1 (no) 2008-02-08
KR20140041831A (ko) 2014-04-04
NO342490B1 (no) 2018-06-04
HRP20120323T4 (hr) 2015-10-09
HK1169321A1 (en) 2013-01-25
PL2444085T3 (pl) 2015-07-31
KR102713358B1 (ko) 2024-10-02
KR20190104244A (ko) 2019-09-06
KR101169832B1 (ko) 2012-07-30
BRPI0610359B1 (pt) 2020-09-24
AU2006248109B2 (en) 2012-11-15
JP6013535B2 (ja) 2016-10-25
RU2448096C3 (ru) 2017-12-11
JP2008540523A (ja) 2008-11-20
JP2021035970A (ja) 2021-03-04
BRPI0610359B8 (pt) 2021-05-25
KR101332889B1 (ko) 2013-11-26
JP2019218352A (ja) 2019-12-26
NO339997B1 (no) 2017-02-27
JP2018100292A (ja) 2018-06-28
CA2608436C (fr) 2015-03-24
LU92338I2 (fr) 2015-10-27
KR101782236B1 (ko) 2017-09-26
CA2608436A1 (fr) 2006-11-23
CN116003328A (zh) 2023-04-25
IL187328A0 (en) 2008-04-13
HRP20120323T1 (en) 2012-05-31
SG10201703816SA (en) 2017-06-29
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
CY2013047I1 (el) 2015-11-04
EP1893196A4 (fr) 2009-03-18
CN101222922B (zh) 2012-04-18
JP2012211190A (ja) 2012-11-01
EP2561871A1 (fr) 2013-02-27
SI2444085T1 (sl) 2015-06-30
NO20076401L (no) 2008-02-08
NO2017019I1 (no) 2017-05-04
CN105037273B (zh) 2019-04-19
HK1112856A1 (en) 2008-09-19
IL243812A0 (en) 2016-04-21
JP2023075313A (ja) 2023-05-30
EP2444085B1 (fr) 2015-03-18
KR20120102140A (ko) 2012-09-17
RU2448096C2 (ru) 2012-04-20
KR101579701B1 (ko) 2015-12-22
KR20240148945A (ko) 2024-10-11
KR102324567B1 (ko) 2021-11-09
IL323480A (en) 2025-11-01
CN105037273A (zh) 2015-11-11
RU2007146462A (ru) 2009-06-20
IL187328A (en) 2016-02-29
RU2638833C2 (ru) 2017-12-18
KR20080014039A (ko) 2008-02-13
JP5150780B2 (ja) 2013-02-27
KR20230003445A (ko) 2023-01-05
ME01992B (fr) 2012-10-30
WO2006124118A1 (fr) 2006-11-23
KR102481886B1 (ko) 2022-12-28
IL258880A (en) 2018-06-28
NZ564223A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
FR13C0071I1 (fr) Compose diarylhydantoine
EP1873153A4 (fr) Compose heterocyclique
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE502006003394D1 (de) Lehnenklappung
DE602005006405D1 (de) Maisabstreifer
DE502006005667D1 (de) Gelenklager
DE502006008475D1 (de) Wasserpumpenflügelrad
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
ATE549324T1 (de) Tetrahydrobenzoxazine
DE502006006857D1 (de) Wingungserregern
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502006004302D1 (de) Verschlusskappe
DE502005005839D1 (de) Feldgeerät
DE602005003547D1 (de) Fahrradantriebsnabe
DE502006001397D1 (de) Lagerbuchse
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006001004D1 (de) Hydrolager
ATE485368T1 (de) Hiv - impfung
DE502006003147D1 (de) Verbundgußplatte
AT501523A3 (de) Estrich
DE502006003210D1 (de) Nohydrogenpolysiloxanen
DE502006000445D1 (de) Mulchmähdeck
DE502006000489D1 (de) Induktionshärtungsanlage